^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or AntiPDL1 Antibodies

    Excerpt:
    ...For subjects with a known BRAF V600-activating mutation combination targeted therapy will be required in addition to anti-PD-1/PD-L1 therapy.3. ...
    Trial ID:
    2019-001923-11
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    IMM60 and Pembrolizumab in Melanoma and NSCLC

    Excerpt:
    ...B-type Raf proto-oncogene (BRAF) mutation status available -...
    Trial ID:
    KEYNOTE-E69
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

    Excerpt:
    ...Melanoma with known BRAFv600 mutation: received BRAF/MEKi therapy before this study....
    Trial ID:
    KEYNOTE-F62
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer

    Excerpt:
    ...BRAF V600 mutation patients must have progressed on, or are intolerant to, BRAF +/- MEK inhibitor therapy....
    Trial ID:
    NCT05620134
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

    Excerpt:
    ...Both BRAF wild-type and mutated melanomas are eligible; BRAF mutated patients are required to have previously progressed on or...
    Trial ID:
    NCT04129515
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

    Excerpt:
    ...Have received a combination of a BRAF inhibitor and a MEK inhibitor if diagnosed with a BRAF mutated melanoma and if clinically indicated; and 5....
    Trial ID:
    Catalyst
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

    Excerpt:
    ......
    Trial ID:
    CICILIA
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

    Excerpt:
    ...BRAF V600 mutant melanoma may have received standard of care targeted therapy (e.g....
    Trial ID:
    KEYNOTE-555
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

    Excerpt:
    ...Irrespective of PD-L1 result and BRAF V600 mutation 4....
    Trial ID:
    NCT05877430
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

    Excerpt:
    ...Consent to the evaluation of the PD-L1 status and BRAF V600 mutation status ; 7....
    Trial ID:
    NEO-MIMAJOR
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

    Excerpt:
    ...- Has testing for a BRAF mutation prior to study entry...
    Trial ID:
    KEYNOTE-161
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

    Excerpt:
    ...- Participants with BRAF gene mutant melanoma must have had a prior treatment regimen that included vemurafenib, dabrafenib, or an approved BRAF gene and/or mitogen-activated protein kinase (MEK) protein inhibitor...
    Trial ID:
    KEYNOTE 002
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)

    Excerpt:
    ...- Has documented BRAF mutation status or is willing to provide a tumor tissue for BRAF genotyping....
    Trial ID:
    Keynote-151
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL

    Excerpt:
    ...4.Has been untreated for advanced disease except as follows: a.BRAF V600 mutation-positive melanoma may have received SOC targeted therapy as 1L therapy for advanced disease (eg, BRAF/MEK inhibitor, alone or in combination). ...
    Trial ID:
    2019-003977-24
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Future Oncol
    Title:

    Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy

    Published date:
    04/20/2022
    Excerpt:
    Advanced BRAF-mutant melanoma patients treated with 1L CPI or TT were selected from a real-world, electronic health record-derived database....CPI was associated with improved survival after adjustment for potential confounders (hazard ratio, 0.75 [95% CI, 0.66–0.87])....This real-world study demonstrated a survival benefit with 1L CPI versus TT.
    DOI:
    10.2217/fon-2021-1536